A detailed history of Quadrant Capital Group LLC transactions in Myriad Genetics Inc stock. As of the latest transaction made, Quadrant Capital Group LLC holds 642 shares of MYGN stock, worth $9,790. This represents 0.0% of its overall portfolio holdings.

Number of Shares
642
Previous 657 2.28%
Holding current value
$9,790
Previous $16,000 6.25%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$23.97 - $28.6 $359 - $429
-15 Reduced 2.28%
642 $17,000
Q2 2024

Aug 12, 2024

SELL
$17.98 - $25.47 $3,649 - $5,170
-203 Reduced 23.6%
657 $16,000
Q1 2024

May 15, 2024

BUY
$17.59 - $23.59 $3,324 - $4,458
189 Added 28.17%
860 $18,000
Q4 2023

Feb 08, 2024

BUY
$13.91 - $21.32 $7,274 - $11,150
523 Added 353.38%
671 $12,000
Q3 2023

Nov 14, 2023

SELL
$15.99 - $23.22 $2,318 - $3,366
-145 Reduced 49.49%
148 $2,000
Q2 2023

Aug 09, 2023

BUY
$17.56 - $23.76 $1,141 - $1,544
65 Added 28.51%
293 $6,000
Q1 2023

May 11, 2023

SELL
$15.26 - $23.75 $5,234 - $8,146
-343 Reduced 60.07%
228 $5,000
Q4 2022

Feb 10, 2023

BUY
$14.51 - $20.99 $5,571 - $8,060
384 Added 205.35%
571 $8,000
Q2 2022

Aug 09, 2022

BUY
$16.45 - $25.88 $1,546 - $2,432
94 Added 101.08%
187 $3,000
Q3 2021

Nov 12, 2021

BUY
$29.97 - $36.66 $2,787 - $3,409
93 New
93 $3,000
Q3 2020

Nov 13, 2020

SELL
$11.25 - $14.75 $31,770 - $41,654
-2,824 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$10.69 - $16.49 $30,188 - $46,567
2,824 New
2,824 $32,000
Q1 2020

May 15, 2020

SELL
$9.78 - $29.53 $10,288 - $31,065
-1,052 Closed
0 $0
Q2 2019

Jul 24, 2019

BUY
$22.67 - $35.0 $21,672 - $33,460
956 Added 995.83%
1,052 $28,000
Q1 2019

Apr 29, 2019

BUY
$26.93 - $34.7 $1,104 - $1,422
41 Added 74.55%
96 $2,000
Q2 2017

Aug 15, 2017

BUY
N/A
55
55 $0

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.23B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.